First Patient Dosed in U.S. Expanded Access Program for TLX2

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a United States (U.S.) expanded access program (EAP, ClinicalTrials.gov ID: NCT06090331) for TLX250-CDx (89Zr-DFO-girentuximab). TLX250-CDx is the Company's first-in-class, non-invasive investigational positron emission tomography (PET) imaging agent in clear cell renal cell carcinoma (ccRCC).

Related Keywords

United States , Switzerland , Melbourne , Victoria , Australia , United Kingdom , Canada , Belgium , Japan , Australian , Mary Jessel , Kyahn Williamson , John Leahy , Drug Administration , Health Canada , Corporate Communications , Telix Pharmaceuticals , Australian Therapeutic Goods Administration , Imaging At Austin Radiological Association In , Global Medical Affairs At Telix , Australian Securities Exchange , Austin Radiological Association , Principal Investigator , Senior Vice President , Global Medical Affairs , Biologics License Application , Offering Compassionate Use , Investigational Medicines , European Economic Area , Telix Pharmaceuticals Limited , Yap , Felix , Food And Drug Administration ,